On October 20, Sansure Biotech disclosed 2022 third quarter report, the company achieved revenue of CNY 4.068 billion in three quarters this year, an increase of 24.52% year-on-year; the net profit attributable to the mother achieved CNY 1.598 billion. The third quarter revenue in 2022 is 1.378 billion, a 10.25% increase compared to the second quarter, and 11.25% increase compared to the third quarter of last year.

It is worth noting that in the first three quarters, Sansure’s R&D investment reached CNY 180 million, a year-on-year increase of 97.44%, far exceeding the growth rate of revenue.

Sansure Biotech attaches importance to technological innovation, continues to enrich its R&D team, enhance its R&D strength, and has launched the layout of several strategic R&D fields such as gene sequencing, early tumor screening, POCT, etc. Currently, the company has more than 100 projects under research. With the high attention and investment in R&D, Sansure Biotech has gained industry-leading technical strength and strong competitive advantages in products. The company is actively laying out strategic production line business expansion and industrial chain extension, and has made good progress.

In September, Sansure’s Human Immunodeficiency Virus Type 1 Nucleic Acid Assay Kit was approved for marketing, which can achieve more accurate, efficient and convenient quantitative nucleic acid testing of HIV-1 virus and provide patients with scientific monitoring of the whole disease process in the treatment of HIV infection.

In the field of gynecological HPV testing, Sansure’s HPV23 typing nucleic acid test was approved in early August, which can efficiently identify 18 high-risk types and 5 low-risk types of HPV, further improving the company's product matrix in the field of HPV DNA testing.

In addition, Sansure Biotech signed a strategic cooperation agreement with QuantuMDx in September, which strengthens the relationship of global R&D and production cooperation in the field of molecular diagnostic POCT between the two parties, and will start in-depth cooperation on the Q-POC platform, the core product of QuantuMDx. Q-POC is an innovative and high-performance portable molecular diagnostic device, which has been awarded CE certification by the European Union. Along with the deepening cooperation, Sansure’s reagent products are expected to further open up the market space in EU with the help of this platform.

Mr. Dai Lizhong, Chairman of Sansure Biotech, said that strengthening and enlarging the biopharmaceutical industry chain is an important part of building an innovative country. The company will continue to increase investment in R&D, further enhance the ability of original innovation and the leading ability of scientific and technological innovation, make efforts to break through a number of key technologies, help improve the independent controllability of the industry chain supply chain, and strive to become a world-class enterprise.